Skip to content
Screener

Dianthus Therapeutics DNTH Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue$396.0KMiss by $2.1K
EPS-$0.97Miss by $0.11
Revenue estimate$398.1K
EPS estimate-$0.86

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$443.9K
EPS estimate-$0.94

Financials

Q3 2025

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$40.3M-34.7%
Net income-$36.8M-46.0%
EPS (diluted)-$0.97-31.1%

Balance sheet

See full
Cash & equivalents$56.0M+66.3%
Total debt$1.3M+313%
Total equity$546.5M+61.7%
Total assets$577.4M+63.0%

Cash flow

See full
Operating cash flow-$30.6M-43.7%
CapEx$5.0K-80.0%
Free cash flow-$30.6M-43.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.57B+67.1%
Enterprise value$1.51B+67.3%
P/S509×+334×

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio17.3×-1.0×

Segments

By product

See full
License$396.0K-81.8%

FAQ

When did Dianthus Therapeutics report Q3 2025 earnings?
Dianthus Therapeutics (DNTH) reported Q3 2025 earnings on November 5, 2025 before market open.
What were Dianthus Therapeutics's Q3 2025 revenue and EPS?
Dianthus Therapeutics reported revenue of $396.0K and eps of $-0.97 for Q3 2025.
Did Dianthus Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $398.1K by $2.1K. EPS missed the consensus estimate of $-0.86 by $0.11.
How did Dianthus Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 81.8% from $2.2M a year earlier and eps declined 31.1% from $-0.74.
Where can I find Dianthus Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-262188) and the 10-Q periodic report (0001193125-25-266920) directly on SEC EDGAR. The filing index links above go to sec.gov.